The nocebo effect challenges the non-medical infliximab switch in practice

Overview of attention for article published in European Journal of Clinical Pharmacology, January 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter: 3 X users

googleplus: 1 Google+ user

Citations

dimensions_citation: 101 Dimensions

Readers on

mendeley: 147 Mendeley

Summary X Google+ Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 563 followers.

The nocebo effect is a big challenge for any proposed switching of therapies, educating patients with clear information will be key for any #adalimumab switches to #biosimilars https://t.co/cdQqmveJCW

12 Nov 2018

Reply Repost Favourite

#Biosimilar #Nocebo Effect: Paper describes "the 1-year results of a pragmatic study on infliximab biosimilar implementation in immune-mediated inflammatory disease patients on the basis of shared decision-making under effectiveness and safety monitoring."